玻璃体内注射阿达木单抗治疗活动性非感染性葡萄膜炎：一项试点研究。

Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.

作者信息

Hamam Rola N, Barikian Anita W, Antonios Rafic S, Abdulaal Marwan R, Alameddine Ramzi M, El Mollayess Georges, Mansour Ahmad M

机构信息

a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.

b Department of Ophthalmology , Université de Montreal , Montreal , Canada.

出版信息

Ocul Immunol Inflamm. 2016 Jun;24(3):319-26. doi: 10.3109/09273948.2014.990041. Epub 2014 Dec 30.

DOI:10.3109/09273948.2014.990041

PMID:25549063

Abstract

PURPOSE

To evaluate the short-term efficacy of intravitreal adalimumab (IVA) for the treatment of eyes with active noninfectious uveitis.

METHODS

Consecutive eyes with active noninfectious uveitis were injected with IVA at 0, 2, then every 4 weeks for total of 26 weeks.

RESULTS

Six out of 7 patients (12 of 13 eyes) completed 26 weeks of treatment. One patient (1 eye) failed treatment. Seven out of 12 eyes had improvement of ≥2 ETDRS lines. Three out of three eyes had resolution of anterior chamber cells. And 9 of 10 eyes with vitreous haze had zero haze at 26 weeks. Five out of 8 eyes with macular edema had complete resolution. Median fluorescein angiography score improved from 14 to 4 on last follow-up.

CONCLUSIONS

IVA was effective in controlling the inflammation, decreasing the macular edema, and improving the best corrected visual acuity in the majority of eyes in this series.

摘要

目的

评估玻璃体内注射阿达木单抗（IVA）治疗活动性非感染性葡萄膜炎的短期疗效。

方法

对患有活动性非感染性葡萄膜炎的连续病例，在第0周、第2周注射IVA，之后每4周注射一次，共治疗26周。

结果

7例患者中的6例（13只眼中的12只）完成了26周的治疗。1例患者（1只眼）治疗失败。12只眼中有7只眼视力提高≥2条早期糖尿病性视网膜病变研究（ETDRS）视力表行。3只眼前房中细胞完全消失。10只伴有玻璃体混浊的眼中有9只在26周时混浊消失。8只伴有黄斑水肿的眼中有5只完全消退。末次随访时荧光素血管造影评分中位数从14降至4。